Market Herald logo

Subscribe

Be the first with the news that moves the market
  • VIVO Cannabis (VIVO) releases results from its 2022 AGM and announces new directors
  • Shareholders voted on and approved moving the number of directors to five
  • All of the officers were previous officers of VIVO
  • A total of 88,982,498 common shares were voted at the meeting, representing over 23 per cent of the votes for all outstanding common shares
  • In addition, VIVO shareholders approved the appointment of MNP LLP as auditor of the company for 2022
  • VIVO Cannabis (VIVO) is up 11.11 per cent, trading at C$0.05 at 12:36 pm EST

VIVO Cannabis (VIVO) has completed its annual general and special meeting of shareholders.

Shareholders elected Ray Laflamme, Glen Huber, Shai Altman, Eric Shipman and Holly Workman as directors of the company.

Laflamme is the founder and the current President of Canna Farms Limited, a wholly-owned subsidiary of the company, and all of the directors are previous directors of VIVO.

“I am pleased with the outcome of today’s AGM,” said Ray Laflamme, VIVO’s CEO and Chair of the Board.

“[…] It is reassuring to have the support of a strong board and dedicated hard-working teams as we work towards leveraging VIVO’s solid position in the Canadian and the global medical cannabis markets,” added Laflamme.

Vivo also appointed Ray Laflamme as CEO, Michael Bumby as CFO, Carole Chan as CCPO and President of Harvest Medicine, Mariana Fonar as General Counsel and Corporate Secretary, and Andreas Sander as President, and European Operations. All of the officers were previous officers of VIVO.

A total of 88,982,498 common shares were voted at the meeting, representing over 23 per cent of the votes for all outstanding common shares.

In addition, VIVO shareholders approved the appointment of MNP LLP as auditor of the company for the 2022 fiscal year.

VIVO Cannabis is a premium cannabis products and services business. It works through its Canna Farms and ABcann business units, holding production and sales licences from Health Canada.

VIVO Cannabis (VIVO) is up 11.11 per cent, trading at C$0.05 at 12:36 pm EST.

More From The Market Herald

" Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Revive Therapeutics (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.

" EnWave (TSXV:ENW) signs technology evaluation agreement with Canadian cannabis cultivator

EnWave Corporation (ENW) has signed an agreement with a Canadian cannabis company to use its 10kW Radiant Energy Vacuum (REV) technology.

" Core One Labs (CSE:COOL) subsidiary Vocan successfully converts Psilocin precursor into Psilocybin

Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin.